Stephen J Shuttleworth
Overview
Explore the profile of Stephen J Shuttleworth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
662
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gyori D, Lim E, Grant F, Spensberger D, Roychoudhuri R, Shuttleworth S, et al.
JCI Insight
. 2018 Jun;
3(11).
PMID: 29875321
Redundancy and compensation provide robustness to biological systems but may contribute to therapy resistance. Both tumor-associated macrophages (TAMs) and Foxp3+ regulatory T (Treg) cells promote tumor progression by limiting antitumor...
2.
Whale A, Colman L, Lensun L, Rogers H, Shuttleworth S
Signal Transduct Target Ther
. 2017 Dec;
2:17063.
PMID: 29279775
Class I phosphoinositide 3-kinase (PI3K) enzymes have attracted considerable attention as drug targets in cancer therapy over the last 20 years. The signaling pathway triggered by class I PI3Ks is...
3.
Ellis J, Neil D, Inston N, Jenkinson E, Drayson M, Hampson P, et al.
Transplantation
. 2016 May;
100(8):1667-74.
PMID: 27222932
Background: Current transplant immunosuppression regimens have numerous limitations. Recent evidence suggests histone deacetylase inhibitors (HDACis) may represent a class of drug with immunosuppressive properties. This study compares cyclosporin A (CyA)...
4.
Large J, Torr J, Raynaud F, Clarke P, Hayes A, Stefano F, et al.
Bioorg Med Chem
. 2011 Jan;
19(2):836-51.
PMID: 21216151
Two classes of trisubstituted pyrimidines related to PI-103 1 have been prepared and their inhibitory activities against phosphatidylinositol 3-kinase (PI3K) p110α were determined. From those with direct 6-aryl substitution compound...
5.
Shuttleworth S, Bailey S, Townsend P
Curr Drug Targets
. 2010 Jun;
11(11):1430-8.
PMID: 20583972
The development of Histone Deacetylase (HDAC) inhibitors has, until recently, principally been driven by their potential as anti-cancer agents. However, there is emerging evidence that HDAC inhibitors could have utility...
6.
Fu J, Shuttleworth S, Connors R, Chai A, Coward P
Bioorg Med Chem Lett
. 2009 Jun;
19(15):4264-7.
PMID: 19553112
The discovery and parallel synthesis of potent, small molecule antagonists of Neuromedin B receptor based on the ary-hexahydro-dibenzodiazepin-1-one core is described.
7.
Folkes A, Ahmadi K, Alderton W, Alix S, Baker S, Box G, et al.
J Med Chem
. 2008 Aug;
51(18):5522-32.
PMID: 18754654
Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/ Akt signaling pathway in a wide variety of tumors. A series of thieno[3,2-d]pyrimidine derivatives were...
8.
Zvelebil M, Waterfield M, Shuttleworth S
Arch Biochem Biophys
. 2008 Jul;
477(2):404-10.
PMID: 18647592
A series of small molecule, ATP-competitive phosphoinositide 3-kinase inhibitors have been examined in homology models of the four class I isoforms, p110alpha, p110beta, p110delta and p110gamma. This analysis provided an...
9.
Gharbi S, Zvelebil M, Shuttleworth S, Hancox T, Saghir N, Timms J, et al.
Biochem J
. 2007 Feb;
404(1):15-21.
PMID: 17302559
The PI3Ks (phosphatidylinositol 3-kinases) regulate cellular signalling networks that are involved in processes linked to the survival, growth, proliferation, metabolism and specialized differentiated functions of cells. The subversion of this...
10.
Shuttleworth S, Connors R, Fu J, Liu J, Lizarzaburu M, Qiu W, et al.
Curr Med Chem
. 2005 Jun;
12(11):1239-81.
PMID: 15974996
This review chronicles original literature dating back to 1992 outlining the applications of parallel synthesis and combinatorial chemistry to the synthesis of compound libraries focused towards specific superfamilies of molecular...